TONMYA

Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

As Tonix Pharmaceuticals transitions from clinical-stage hopeful to commercial biotech on the back of its new fibromyalgia drug Tonmya, Wall Street is split between blockbuster dreams and dilution fears. TNXP Stock on December 4, 2025: Price, Volume and Volatility Tonix

4 December 2025

Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) heads into Sunday, November 23, 2025, with its first commercial fibromyalgia drug now on pharmacy shelves, a beefed‑up share repurchase program, and a sharply expanded at‑the‑market (ATM) equity facility. Together, those moves are redefining

23 November 2025

Company News · Financial Analysis · Investment Strategies · Pharmaceuticals · Stock Market

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) moved sharply higher today after the company confirmed that TONMYA™ (cyclobenzaprine HCl sublingual tablets), its newly approved fibromyalgia treatment, is now commercially available by prescription across the United States. GlobeNewswire+1 TONMYA Officially Launches in

17 November 2025

Drug Approvals · Fibromyalgia · Healthcare News · Medical Innovations · NASDAQ:TNXP · Pharmaceuticals